Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis
- PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with RRP PAPZIMEOS received full approval from the FDA for the treatment of adults with RRP; a confirmatory clinical trial is no longer required RRP is a rare, debilitating, and potentially life-threatening disease caused by chronic HPV 6 or HPV 11 infection, which results in recurrent benign tumors in the respiratory tract; RRP affects an estimated 27,000 adult patients in the US PAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy designed to generate an immune response directed against papilloma cells expressing HPV 6/11—the first and only approved therapy to treat the root cause of RRP Precigen will host a conference call on Monday, August 18 at 8:00 AM ET GERMANTOWN, Md , Aug. 15, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has approved PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). PAPZIMEOS is the first and only FDA-approved therapy for the treatment of adults with RRP.
- 08/15/2025
|
Precigen: August Is Pivotal For This Biotech Innovator
- Precigen's future hinges on the FDA's approval of PRGN-2012, with a pivotal decision expected August 27, 2025. PRGN-2012 shows strong efficacy and safety, potentially transforming the treatment of Recurrent Respiratory Papillomatosis and opening up a $2 billion global market opportunity. Despite promising science, Precigen has long-faced severe financial challenges and a very short cash runway into 2026.
- 07/07/2025
|
Precigen Reports First Quarter 2025 Financial Results and Business Updates
- PRGN-2012 has the potential to be the first- and best-in-class treatment for RRP Company's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA target action date set for August 27, 2025 RRP is a rare, debilitating chronic disease with approximately 27,000 adult patients in the US and more than 125,000 patients outside of the US Company continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launch Company and Recurrent Respiratory Papillomatosis Foundation to host the 2025 International RRP Awareness Day on June 11 Cash, cash equivalents, and investments of $81.0 million as of March 31, 2025 are anticipated to fund operations into 2026, beyond the potential 2025 commercial launch of PRGN-2012 GERMANTOWN, Md. , May 14, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2025 financial results and business updates.
- 05/14/2025
|
Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th
- – International event will raise awareness and bring together RRP patients , caregivers, and the healthcare community supporting them – – Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection – – There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury – GERMANTOWN, Md. , April 16, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will team up again with the Recurrent Respiratory Papillomatosis Foundation (RRPF) to co-host the annual RRP Awareness Day on June 11, 2025.
- 04/16/2025
|
Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript
- Precigen, Inc. (NASDAQ:PGEN ) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants Steven Harasym - IR Helen Sabzevari - President and CEO Rutul Shah - COO Phil Tennant - CCO Harry Thomasian - CFO Conference Call Participants Jason Butler - Citizens Carolina Ibanez Ventoso - Stifel Swayampakula Ramakanth - H.C. Wainwright Jennifer Kim - Cantor Brian Cheng - JPMorgan Operator Good evening, and welcome to the Precigen's Full Year 2024 Financial Results and Business Update Call.
- 03/19/2025
|
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates
- Precigen, Inc. (PGEN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.09 per share a year ago.
- 03/19/2025
|
Precigen Reports Full Year 2024 Financial Results and Business Updates
- FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action date for August 27, 2025 Results from pivotal clinical study of PRGN-2012 were published in The Lancet Respiratory Medicine PRGN-2012 treatment demonstrated durable complete responses with median duration of response of two years, with some complete responders surgery-free beyond three years as of August 28, 2024 data cutoff Company continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launch Company ended 2024 with $97.9 million in cash, cash equivalents, and investments, extending its cash runway into 2026, beyond potential 2025 commercial launch of PRGN-2012 GERMANTOWN, Md. , March 19, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced full year 2024 financial results and business updates.
- 03/19/2025
|
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th
- GERMANTOWN, Md. , March 13, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year 2024 financial results and provide business updates on Wednesday, March 19, 2025.
- 03/13/2025
|
Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement
- BLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge because there is no FDA approved drugs for RRP. Also, there are an estimated 27,000 people in the United States who have it. PGEN is looking to form a strategic partnership or collaboration agreement to advance its UltraCAR-Ts. This technology is crucial because it could change CAR-T landscape for the better.
- 02/28/2025
|
FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025
- – Priority review reduces the BLA review timeline to 6-months and is granted to therapies that, if approved, would provide significant improvements in the treatment, diagnosis or prevention of serious conditions – – If approved, PRGN-2012 would be the first and only available FDA-approved therapy for eligible patients with RRP, a rare and devastating chronic disease for which the current standard-of-care is repeated surgeries – GERMANTOWN, Md. , Feb. 25, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the US Food and Drug Administration (FDA) has accepted the company's biologics license application (BLA) for PRGN-2012 (nonproprietary name: zopapogene imadenovec † ), an investigational AdenoVerse ® gene therapy for the treatment of adults with recurrent respiratory papillomatosis (RRP).
- 02/25/2025
|
Precigen, Inc. (PGEN) Just Flashed Golden Cross Signal: Do You Buy?
- Precigen, Inc. (PGEN) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PGEN's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
- 02/20/2025
|
Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference
- – PRGN-2012 has potential to be first FDA-approved therapeutic for treatment of RRP, a rare and devastating chronic disease – – Company completed BLA submission for PRGN-2012 for treatment of adults with RRP – – Commercial readiness activities underway in anticipation of potential launch of PRGN-2012; Company started 2025 with approximately $100 million cash on-hand* with cash runway well into 2026, beyond the anticipated launch in the second half of 2025 – – According to recently updated internal analysis derived from review of claims data, the market opportunity for PRGN-2012 in RRP is estimated to be approximately 27,000 adult patients in the US – – Immense market potential for AdenoVerse platform in other HPV6/11-driven indications, such as genital warts, which has significant unmet need with annual global incidence of more than 4 million and prevalence of more than 25 million, and HPV16/18-driven indications, such as cervical cancer and head and neck cancers – – Company presentation on Thursday, January 16, 2025 at 9:00 AM PT in San Francisco – GERMANTOWN, Md. , Jan. 13, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced highlights for the upcoming company presentation at the 43rd Annual J.P.
- 01/13/2025
|
Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- GERMANTOWN, Md. , Jan. 9, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present at the 43rd Annual J.P.
- 01/09/2025
|
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?
- The upside in Precigen's stock comes after it completes the rolling submission of an FDA filing for its first potentially marketed product.
- 01/02/2025
|
Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis
- – PRGN-2012 has the potential to be the first FDA-approved therapeutic for the treatment of adults with RRP, a rare and devastating chronic disease for which the current standard-of-care is repeated surgeries – – PRGN-2012 received Breakthrough Therapy Designation from the FDA and Orphan Drug Designation from the FDA and the European Commission – – The BLA, under an accelerated approval pathway, is supported by data from the Phase 1/2 pivotal study in which more than 50% of patients achieved Complete Response and more than 85% of patients had a decrease in surgical interventions in the year after PRGN-2012 treatment compared to the year prior to treatment – – PRGN-2012 was well-tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2 – GERMANTOWN, Md. , Dec. 30, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the completion of the rolling submission for a biologics license application (BLA) to the US Food and Drug Administration (FDA) for PRGN-2012 (INN: zopapogene imadenovec † ) for the treatment of adult patients with recurrent respiratory papillomatosis (RRP).
- 12/30/2024
|
Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock
- GERMANTOWN, Md. , Dec. 27, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that it has entered into a securities purchase agreement for the sale of its 8.00% Series A Convertible Perpetual Preferred Stock (Preferred Stock) in a private placement.
- 12/27/2024
|
Precigen, Inc. (PGEN) Reports Q3 Loss, Lags Revenue Estimates
- Precigen, Inc. (PGEN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.08 per share a year ago.
- 11/14/2024
|
Precigen Reports Third Quarter 2024 Financial Results and Business Updates
- – Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path for fourth quarter 2024 rolling BLA submission for PRGN-2012 † in RRP under accelerated approval pathway – – Commercial and manufacturing readiness campaign underway for PRGN-2012 in anticipation of a potential 2025 launch – – Confirmatory clinical trial for PRGN-2012 in RRP was initiated in accordance with guidance from FDA to initiate prior to submission of the BLA; continuing enrollment – – Preparing for end of Phase 1b meeting with FDA in early 2025 for PRGN-3006 in AML – – Presented preclinical data at SITC 2024 for PRGN-3008, a next generation UltraCAR-T targeting CD19 showcasing potential to be best-in-class CD19-targeting CAR-T treatment in oncology and autoimmunity – GERMANTOWN, Md. , Nov. 14, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter 2024 financial results and business updates.
- 11/14/2024
|
Precigen to Participate in the Stifel 2024 Healthcare Conference
- GERMANTOWN, Md. , Nov. 12, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat on Tuesday, November 19, 2024 from 10:55 to 11:25 AM ET at the Stifel 2024 Healthcare Conference taking place November 18 to 19, 2024 in New York.
- 11/12/2024
|
Precigen to Participate in the 2024 Cantor Global Healthcare Conference
- GERMANTOWN, Md. , Sept. 16, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat on Wednesday, September 18, 2024 from 9:45 to 10:15 AM ET at the 2024 Cantor Global Healthcare Conference taking place September 17 to 19, 2024 in New York.
- 09/16/2024
|
3 Penny Stocks To Buy With Just $50
- Penny stocks are an interesting category. While they have the potential to produce significant long-run gains, you should never bet money on these stocks that you can't afford to lose.
- 09/15/2024
|
3 Penny Stocks to Buy With $500
- Are you interested in investing in penny stocks?
- 08/30/2024
|
Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session
- U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Thursday.
- 08/15/2024
|
Precigen, Inc. (PGEN) Q2 2024 Earnings Call Transcript
- Precigen, Inc. (NASDAQ:PGEN ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Steven Harasym - VP, IR Helen Sabzevari - President & CEO Harry Thomasian - CFO Phil Tennant - Chief Commercial Officer Rutul Shah - COO Conference Call Participants Carolina Ibanez Ventoso - Stifel Jason Butler - Citizens JMP Swayampakula Ramakanth - H.C. Wainwright Jennifer Kim - Cantor Fitzgerald Operator Good evening and welcome to the Precigen's Second Quarter and First Half 2024 Financial Results Call.
- 08/14/2024
|
Precigen, Inc. (PGEN) Reports Q2 Loss, Misses Revenue Estimates
- Precigen, Inc. (PGEN) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago.
- 08/14/2024
|
Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates
- – In June 2024, the Company announced groundbreaking pivotal study data for PRGN-2012 gene therapy at the 2024 ASCO annual meeting in which more than half of RRP patients achieved Complete Response – – In July 2024, the Company appointed Phil Tennant as Chief Commercial Officer to spearhead potential PRGN-2012 commercial launch – – In August 2024, the Company announced a strategic reprioritization of its pipeline to focus on advancement of its lead program, PRGN-2012 in RRP – – PRGN-2012 rolling BLA submission, under an accelerated approval pathway, is anticipated in the second half of 2024; the Company has initiated enrollment in the confirmatory clinical trial of PRGN-2012 – – In August 2024, the Company strengthened its cash position by raising approximately $31.4 million via a public offering of common stoc k – GERMANTOWN, Md. , Aug. 14, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced second quarter and first half 2024 financial results and business updates.
- 08/14/2024
|
Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th
- GERMANTOWN, Md. , Aug. 9, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2024 financial results and provide business updates on Wednesday, August 14, 2024.
- 08/09/2024
|
Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock
- GERMANTOWN, Md. , Aug. 7, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 35,294,118 shares of its common stock at a public offering price of $0.85 per share.
- 08/07/2024
|
Earnings Preview: Precigen, Inc. (PGEN) Q2 Earnings Expected to Decline
- Precigen (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/07/2024
|
Precigen Announces Proposed $30 Million Public Offering of Common Stock
- GERMANTOWN, Md. , Aug. 6, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced a $30.0 million underwritten public offering of its common stock.
- 08/06/2024
|
Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch
- – PRGN-2012 is on track for a rolling BLA submission under an accelerated approval pathway; patient enrollment initiated in the confirmatory clinical trial – GERMANTOWN, Md. , Aug. 6, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced a strategic reprioritization of the Company's clinical portfolio and streamlining of resources, including a reduction of over 20% of its workforce, to focus on potential commercialization of the PRGN-2012 AdenoVerse ® gene therapy for the treatment of recurrent respiratory papillomatosis (RRP).
- 08/06/2024
|
Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch
- – Company strengthens focus on building and optimizing commercial readiness and pre-launch activities for PRGN-2012 in recurrent respiratory papillomatosis – GERMANTOWN, Md. , July 23, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Phil Tennant as the Company's chief commercial officer.
- 07/23/2024
|
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
- – Phase 1/2 pivotal study met the primary safety and efficacy endpoints – – 51% (18 out of 35) of patients achieved Complete Response, requiring no surgeries after treatment with PRGN-2012; complete responses have been durable beyond 12 months with median duration of follow up of 20 months as of data cutoff – – 86% of patients (30 out of 35) had a decrease in surgical interventions in the year after PRGN-2012 treatment compared to the year prior to treatment; RRP surgeries reduced from a median of 4 pre-treatment to 0 post-treatment – – PRGN-2012 was well-tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2 – – PRGN-2012 treatment induced HPV 6/11-specific T cell responses in RRP patients with a significantly greater expansion of peripheral HPV-specific T cells in responders compared with non-responders – – PRGN-2012 significantly (p < 0.0001) improved Derkay and quality of life scores in complete responders – – RRP is a rare, devastating HPV-mediated chronic disease characterized by growth of benign tumors for which the current standard-of-care is repeated surgeries ; if approved, PRGN-2012 has the potential to be the first FDA-approved therapeutic for the treatment of RRP – – Clinical data associated with favorable safety, strong efficacy, ease of administration, and immunological responses, position PRGN-2012 to potentially be the preferred treatment-of-choice for RRP – – PRGN-2012 rolling BLA submission, under an accelerated approval pathway, is anticipated in the second half of 2024 – – Precigen to host webcast event today at 6:00 PM CT / 7:00 PM ET – GERMANTOWN, Md. , June 3, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today released positive Phase 1/2 pivotal study results for the investigational PRGN-2012 off-the-shelf (OTS) AdenoVerse ® gene therapy in patients with recurrent respiratory papillomatosis (RRP).
- 06/03/2024
|
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
- GERMANTOWN, Md. , May 23, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will host a webcast on June 3, 2024 at 6:00 PM CT/7:00 PM ET following the late-breaking oral presentation of results from the pivotal study of PRGN-2012 for the treatment of recurrent respiratory papillomatosis (RRP) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
- 05/23/2024
|
Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates
- Precigen, Inc. (PGEN) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago.
- 05/14/2024
|
Precigen Reports First Quarter 2024 Financial Results and Business Updates
- – Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking oral presentation on June 3 rd – – Company to host a conference call on June 3 rd following the PRGN-2012 ASCO presentation to discuss in detail the pivotal study results and provide business updates – – PRGN-2012 rolling BLA submission, under an accelerated approval pathway, is anticipated in the second half of 2024; commercial readiness activities underway for a potential launch in 2025 – – Two trial-in-progress presentations for PRGN-2009 in combination with pembrolizumab for the treatment of recurrent/metastatic cervical cancer and oropharyngeal cancer to be presented at ASCO – – Company and the Recurrent Respiratory Papillomatosis Foundation to co-sponsor the inaugural RRP Awareness Day on June 11 th to raise awareness and bring together individuals living with RRP, caregivers, clinicians, and government officials – – Cash, cash equivalents, and short-term investments totaled $44.8 million as of March 31, 2024 – GERMANTOWN, Md. , May 14, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2024 financial results and business updates.
- 05/14/2024
|
Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting
- GERMANTOWN, Md. , May 8, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will report first quarter 2024 financial results after the market close on Tuesday, May 14, 2024.
- 05/08/2024
|
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
- GERMANTOWN, Md. , April 24, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical data from the pivotal Phase 2 study of PRGN-2012 AdenoVerse immunotherapy for the treatment of patients with recurrent respiratory papillomatosis (RRP) will be presented in a late-breaking oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 31 to June 4, 2024 at McCormick Place in Chicago, Illinois.
- 04/24/2024
|
Actym Therapeutics Appoints Thomas Smart as CEO
- BERKELEY, Calif. , April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer.
- 04/24/2024
|
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
- – Inaugural multi-stakeholder event on June 11th (6/11) will raise awareness and bring together individuals living with RRP, caregivers, clinicians, and government officials – – RRP is a rare, HPV-driven disease with no FDA-approved therapeutic – GERMANTOWN, Md. , March 28, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company has teamed up with the Recurrent Respiratory Papillomatosis Foundation (RRPF) to launch the first RRP Awareness Day™ on June 11, 2024, a multi-stakeholder event to raise awareness about recurrent respiratory papillomatosis (RRP) and bring together RRP patients and their caregivers to encourage new connections and build community among those interested in and affected by this devastating disease.
- 03/28/2024
|
Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript
- Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript
- 03/19/2024
|
Precigen Reports Full Year 2023 Financial Results and Business Updates
- – Significant progress made in the development of the PRGN-2012 AdenoVerse immunotherapy for the treatment of RRP; Precigen plans to submit a BLA under an accelerated approval pathway in the second half of 2024; ramping up commercial readiness activities for a potential launch in 2025 – – Precigen's PRGN-2012 received the first Breakthrough Therapy Designation and accelerated approval pathway from the FDA for the treatment of RRP – – Precigen received IND clearance for a randomized Phase 2 study of PRGN-2009 AdenoVerse immunotherapy in combination with pembrolizumab in HPV-associated recurrent/metastatic cervical cancer; study now active and recruiting patients – – Interim data from the ongoing Phase 1b study of PRGN-3006 UltraCAR-T in relapsed/refractory AML anticipated in the second half of 2024 – – Preliminary data from the Phase 1 study of PRGN-3007 next generation UltraCAR-T in ROR1+ advanced cancers anticipated in the second half of 2024 – – Cash, cash equivalents, short-term and long-term investments totaled $62.9 million as of December 31, 2023 – – Continued focus on cost containment resulted in a reduction in SG&A costs of 16% for the twelve months ended December 31, 2023, compared to the prior year period – GERMANTOWN, Md. , March 19, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced full year 2023 financial results and business updates.
- 03/19/2024
|
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
- GERMANTOWN, Md. , March 12, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Cantor Fitzgerald will be hosting a virtual fireside chat with Precigen on Monday, March 25, 2024 at 1:00 PM ET to discuss the investigational PRGN-2012 AdenoVerse ™ immunotherapy for the treatment of recurrent respiratory papillomatosis (RRP).
- 03/12/2024
|
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
- GERMANTOWN, Md. , March 5, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will report fourth quarter and full year 2023 financial results on Tuesday, March 19, 2024.
- 03/05/2024
|
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- GERMANTOWN, Md. , Feb. 6, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference taking place virtually from February 13 to February 14, 2024.
- 02/06/2024
|
Precigen: RRP Targeting With AdenoVerse Technology Platform
- FDA agreed to allow phase 1/2 study to serve as the basis for being able to file for Accelerated Approval of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. A BLA filing of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis is expected in the 2nd half of 2024. It is projected that it could earn $2 billion in peak sales globally of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis.
- 01/19/2024
|
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
- – Designation is an important step toward bringing this potentially life-changing therapy to European patients – – EU Orphan Drug Designation is the first regulatory designation for a gorilla adenovector based immunotherapy outside of the United States for the Company – GERMANTOWN, Md. , Jan. 16, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the European Commission (EC) has granted Orphan Drug Designation for the Company's first-in-class investigational medicine PRGN-2012 for the treatment of recurrent respiratory papillomatosis (RRP).
- 01/16/2024
|
Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference
- – PRGN-2012 Phase 2 pivotal study data in RRP is anticipated in the second quarter of 2024; the Company plans to submit a BLA under an accelerated approval pathway in the second half of 2024; commercial readiness preparations are underway for a potential launch in 2025 – – Company presentation scheduled for January 10 at 5:15 PM PST – GERMANTOWN, Md. , Jan. 8, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today released highlights of pipeline updates to be presented at the 42nd Annual J.P.
- 01/08/2024
|
Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- GERMANTOWN, Md., Dec. 18, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview at the 42nd Annual J.P.
- 12/18/2023
|
5 ‘Jackpot' Stocks to Buy for 2024 for 10X Gains
- Last week, I revealed five “jackpot” stocks to buy for 2024.
- 12/04/2023
|
Precigen to Participate in the JMP Securities Hematology and Oncology Summit
- GERMANTOWN, Md. , Nov. 29, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 6, 2023 at 3:00 PM ET.
- 11/29/2023
|
3 Penny Stocks to Buy to Turn $1 into $100: November 2023
- In this market cycle that we are experiencing, new opportunities arise to take advantage of over the next few years. There is no better way to take advantage of these opportunities than through penny stocks.
- 11/22/2023
|
Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs
- – Based on FDA confirmation in August 2023 that the ongoing Phase 1/2 single-arm study of PRGN-2012 in RRP will serve as the pivotal study to support BLA submission under an accelerated approval request, the Company has expedited efforts to attain commercial readiness – – Full results of the Phase 1 portion of the ongoing Phase 1/2 study of PRGN-2012 were published in the peer-reviewed journal, Science Translational Medicine, and presented in an oral presentation at the ESGCT 30th Annual Congress – – Enrollment and dosing was completed in the Phase 2 study of PRGN-2012 in RRP; Phase 2 study completion expected in the second quarter of 2024 – – Cash, cash equivalents, short-term and long-term investments totaled $79.0 million as of September 30, 2023; cash runway projected into 2025 – – Continued focus on cost containment resulted in a reduction in SG&A costs of 17% for the nine months ended September 30, 2023, compared to the prior year over the same period – GERMANTOWN, Md. , Nov. 9, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter 2023 financial results and progress of clinical programs.
- 11/09/2023
|
Precigen to Participate in Upcoming Leading Investor and Industry Conferences
- GERMANTOWN, Md. , Sept. 19, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in the following upcoming investor and industry conferences: Cantor Global Healthcare Conference 2023 Fireside chat on Tuesday, September 26 at 4:55 PM ET New York, NY Cell & Gene Meeting on the Mesa Company presentation on Wednesday, October 11, 2023 at 3:30 PM PT Carlsbad, CA Cantor AML Virtual Panel Panel discussion on acute myeloid leukemia (AML) on Thursday, October 26, 2023 at 2:00 PM ET Virtual Participants may view details for these events through Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.
- 09/19/2023
|
Should You Buy Precigen, Inc. (PGEN) After Golden Cross?
- Precigen, Inc. (PGEN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, PGEN's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
- 09/05/2023
|
10 Top Penny Stocks To Buy According To Insiders In August
- Engaging in the world of low-cost stocks often referred to as penny stocks, is appealing to those looking to capitalize on the potential upsides of the stock market. These stocks, priced below $5, are known for their intrinsic risk.
- 08/17/2023
|
Precigen, Inc. (PGEN) Q2 2023 Earnings Call Transcript
- Precigen, Inc. (NASDAQ:PGEN ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Steve Harasym - Vice President, Investor Relations Helen Sabzevari - President & Chief Executive Officer Harry Thomasian - Chief Financial Officer Conference Call Participants Jason Butler - JMP Securities Jennifer Kim - Cantor Fitzgerald Arthur He - H.C. Wainwright Ben Burnett - Stifel Brian Cheng - JPMorgan Operator Good morning and welcome to the Precigen Second Quarter and First Half 2023 Financial Results and Business Update Call.
- 08/09/2023
|
Hero or Zero? 3 High-Risk Penny Stocks to Make You Rich
- High-risk penny stocks have long tempted investors with the potential for significant returns. However, it is crucial to acknowledge the inherent risks associated with these speculative investments.
- 05/19/2023
|
7 High-Potential Penny Stocks in the Biotech Sector
- Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ: AXSM ), for example.
- 05/04/2023
|
Precigen to Announce First Quarter 2023 Financial Results on May 10th
- GERMANTOWN, Md. , May 3, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release first quarter 2023 financial results on Wednesday, May 10, 2023.
- 05/03/2023
|
Strong Small-Cap Insider Buys: Q1 2023
- Strong Small-Cap Insider Buys: Q1 2023.
- 04/26/2023
|
5 Penny Stocks To Watch Today; Is It Time To Buy?
- Penny stocks to watch today. The post 5 Penny Stocks To Watch Today; Is It Time To Buy?
- 04/20/2023
|
Founders at These 7 Companies Are Loading Up on Their Stock. Should You?
- The Executive Vice President of the Dish Network (NASDAQ: DISH ) is Jim DeFranco. He also happens to be a co-founder of the satellite TV provider.
- 03/15/2023
|
Here's Why Precigen, Inc. (PGEN) Is a Great 'Buy the Bottom' Stock Now
- Precigen, Inc. (PGEN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
- 03/14/2023
|
5 Penny Stocks To Buy According To Analysts, Targets Up To 952%
- Penny stocks to buy according to analysts in 2023 The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 952% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 03/07/2023
|
3 Penny Stocks The Insiders Are Buying
- Penny stocks come with many risks, but with those risks come the potential for great rewards. While there is no guarantee which penny stocks will deliver those rewards, following the insiders is 1 way to find them.
- 02/28/2023
|
Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week
- Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.
- 02/16/2023
|
3 Penny Stocks To Buy According To Insider Bets Up To $25 Million
- Penny stocks to buy according to insider trades this quarter. The post 3 Penny Stocks To Buy According To Insider Bets Up To $25 Million appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 02/06/2023
|
Precigen, Inc. (PGEN) Moves to Buy: Rationale Behind the Upgrade
- Precigen, Inc. (PGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 01/27/2023
|
Precigen to Present at the 41st Annual J.P. Morgan Healthcare Conference
- GERMANTOWN, Md. , Dec. 19, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview at the 41st Annual J.P.
- 12/19/2022
|
Precigen, Inc. (PGEN) Q3 2022 Earnings Call Transcript
- Precigen, Inc. (NASDAQ:PGEN ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Steve Harasym - Vice President, Investor Relations Helen Sabzevari - President & Chief Executive Officer Harry Thomasian - Chief Financial Officer Conference Call Participants Jason Butler - JMP Securities Ben Burnett - Stifel Arthur He - H.C. Wainwright Jennifer Kim - Cantor Fitzgerald Operator Good day, and welcome to the Precigen Third Quarter 2022 Financial Results Conference Call.
- 11/09/2022
|
Precigen, Inc. (PGEN) Reports Q3 Loss, Lags Revenue Estimates
- Precigen, Inc. (PGEN) delivered earnings and revenue surprises of -140% and 67.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/09/2022
|
Penny Stocks To Buy Now: 3 To Watch Under $3
- Penny stocks to buy for under $3 The post Penny Stocks To Buy Now: 3 To Watch Under $3 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/22/2022
|
Circling Back On Precigen
- Today, we circle back on Precigen, a biotech firm that was once part of Intrexon. Precigen is advancing several drug candidates in its pipeline and recently agreed to a divesture than significantly bolstered its financial situation.
- 08/23/2022
|
Precigen, Inc. (PGEN) CEO Helen Sabzevari on Q2 2022 Results - Earnings Call Transcript
- Precigen, Inc. (NASDAQ:PGEN ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Steven Harasym - Vice President and Head of Investor Relations Helen Sabzevari - President and Chief Executive Officer Harry Thomasian - Chief Financial Officer Conference Call Participants Nick Abbott - Wells Fargo Securities, LLC Jason Butler - JMP Securities, LLC Jennifer Kim - Cantor Fitzgerald & Co. Operator Good day, and welcome to the Precigen Second Quarter and First Half 2022 Financial Results Conference Call. After today's presentation, there will be an opportunity to ask questions.
- 08/08/2022
|
Precigen, Inc. (PGEN) Reports Q2 Loss, Lags Revenue Estimates
- Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 18.75% and 83.41%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/08/2022
|
Analysts Estimate Precigen, Inc. (PGEN) to Report a Decline in Earnings: What to Look Out for
- Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/01/2022
|
Precigen, Inc. (PGEN) Upgraded to Buy: Here's What You Should Know
- Precigen, Inc. (PGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 07/25/2022
|
This Analyst Believes Precigen's Non-Healthcare Divesture Removes Financial Overhang
- Yesterday, Precigen Inc (NASDAQ: PGEN) agreed to sell its non-healthcare subsidiary to URUS. HC Wainwright says they are encouraged by the divestiture of the company's non-core business and believe management deserves much credit, especially against the backdrop of the.
- 07/06/2022
|
Why Precigen Shares Are Gaining Today
- Precigen Inc (NASDAQ: PGEN) has agreed to sell its subsidiary Trans Ova Genetics, an animal reproductive technologies company, to URUS, a holding company with cooperative and private ownership. The deal consideration includes $170 million in upfront cash and up to $10 million earn-.
- 07/05/2022
|
Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates
- Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 28.57% and 53.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/09/2022
|
Precigen (PGEN) Up on FDA Fast Track Tag for CAR-T Candidate
- Precigen (PGEN) is developing CAR T therapy candidate, PRGN-3006 UltraCAR-T, for treating acute myeloid leukemia in a phase I study. The FDA grants Fast Track designation.
- 04/05/2022
|
Precigen, Inc. (PGEN) Reports Q4 Loss, Tops Revenue Estimates
- Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 7.14% and 14.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/01/2022
|
Here's Why Precigen, Inc. (PGEN) Could be Great Choice for a Bottom Fisher
- Precigen, Inc. (PGEN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
- 01/11/2022
|
Precigen: A Substantially Undervalued And Differentiated Gene Therapy Company
- Precigen: A Substantially Undervalued And Differentiated Gene Therapy Company
- 01/10/2022
|
3 Synthetic Biology Stocks in Focus With Strong Potential
- Here we discuss three stocks - CDXS, PGEN, VERV - engaged in the field of scientific biology that investors may keep a tab of as these have the potential to generate wealth for them going forward.
- 12/24/2021
|
Precigen Reveals Early Data From CAR-T Candidate In Blood Cancer Patients
- Precigen Inc (NASDAQ: PGEN) presented positive interim data at the ASH Annual Meeting and Exposition from the ongoing Phase 1/1b study of PRGN-3006 UltraCAR-T in relapsed or refractory (r/r) acute myeloid leukemia and higher-risk myelodysplastic syndromes. PRGN-3006 UltraCAR-T is a multigenic autologous CAR-T simultaneously expressing a CAR targeting CD33.
- 12/14/2021
|
Is the Options Market Predicting a Spike in Precigen (PGEN) Stock?
- Investors need to pay close attention to Precigen (PGEN) stock based on the movements in the options market lately.
- 11/24/2021
|
Precigen Appoints Harry Thomasian Jr. as Chief Financial Officer
- GERMANTOWN, Md., Oct. 12, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Harry Thomasian Jr. as the Company's chief financial officer (CFO), effective October 18, 2021.
- 10/12/2021
|
Implied Volatility Surging for Precigen (PGEN) Stock Options
- Investors need to pay close attention to Precigen (PGEN) stock based on the movements in the options market lately.
- 10/04/2021
|
Precigen ActoBio Announces Additional Positive Interim Data from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes
- GERMANTOWN, Md., Oct. 1, 2021 /PRNewswire/ -- Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced additional positive interim data from the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics™ for the treatment of recent-onset type 1 diabetes (T1D) (clinical trial identifier: NCT03751007, EudraCT 2017-002871-24).
- 10/01/2021
|
Precigen to Present at the 2021 Wells Fargo Virtual Healthcare Conference and the H.C. Wainwright 23rd Annual Global Investment Conference
- GERMANTOWN, Md., Sept. 1, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in two upcoming conferences.
- 09/01/2021
|
Precigen, Inc. (PGEN) CEO Helen Sabzevari on Q2 2021 Results - Earnings Call Transcript
- Precigen, Inc. (PGEN) CEO Helen Sabzevari on Q2 2021 Results - Earnings Call Transcript
- 08/09/2021
|
Precigen, Inc. (PGEN) Reports Q2 Loss, Tops Revenue Estimates
- Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 16.67% and 49.38%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/09/2021
|
Precigen: Q2 Earnings Insights
- Shares of Precigen (NASDAQ:PGEN) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 61.54% year over year to ($0.10), which beat the estimate of ($0.12).
- 08/09/2021
|
Precigen to Announce Second Quarter and First Half 2021 Financial Results on August 9th
- GERMANTOWN, Md., Aug. 2, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2021 financial results after the market closes on Monday, August 9, 2021.
- 08/02/2021
|
Precigen Stock Surges On Positive AG019 Data for Chronic Treatment Of Type 1 Diabetes
- Precigen Inc's (NASDAQ: PGEN) subsidiary Precigen ActoBio announced topline results from the Phase 1b/2a study evaluating AG019 ActoBiotics to treat recent-onset type 1 diabetes (T1D). Results were presented at the Federation of Clinical Immunology Societies 2021.
- 06/11/2021
|
Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes
- GERMANTOWN, Md., June 10, 2021 /PRNewswire/ -- Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced positive topline results for the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics™ for the treatment of recent-onset type 1 diabetes (T1D) (clinical trial identifier: NCT03751007, EudraCT 2017-002871-24).
- 06/10/2021
|
Precigen to Present at the JMP Securities Life Sciences Conference
- GERMANTOWN, Md,, June 10, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat at the annual JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 11:00 AM ET. Participants may access the live webcasts of the virtual events through Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.
- 06/10/2021
|
Precigen Reports First Quarter 2021 Financial Results
- GERMANTOWN, Md., May 10, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2021 financial results.
- 05/10/2021
|
Precigen Announces Departure of Chief Financial Officer
- GERMANTOWN, Md., March 30, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that by mutual agreement Rick Sterling is stepping down from his position as Chief Financial Officer effective April 2, 2021.
- 03/30/2021
|
Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)
- GERMANTOWN, Md., March 23, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the first patient has been dosed in the Phase I study of PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy in adult patients with recurrent respiratory papillomatosis (RRP) (clinical trial identifier: NCT04724980).
- 03/23/2021
|
Precigen Receives FDA Orphan Drug Designation for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)
- GERMANTOWN, Md., March 18, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy for recurrent respiratory papillomatosis (RRP).
- 03/18/2021
|
Precigen, Inc. (PGEN) CEO Helen Sabzevari on Q4 2020 Results - Earnings Call Transcript
- Precigen, Inc. (PGEN) CEO Helen Sabzevari on Q4 2020 Results - Earnings Call Transcript
- 03/02/2021
|
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates
- Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 31.25% and -16.13%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/01/2021
|
Will Precigen, Inc. (PGEN) Report Negative Q4 Earnings? What You Should Know
- Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/22/2021
|
3 Troll-able Stocks That Could Be the Next GME
- The next GME will be hard to find, but these three stocks could be solid candidates for a potential short squeeze. The post 3 Troll-able Stocks That Could Be the Next GME appeared first on InvestorPlace.
- 02/17/2021
|
10 Short Squeeze Candidates Under $10
- The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causing what's known as a short squeeze.
- 01/30/2021
|
Precigen Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
- GERMANTOWN, Md., Jan. 26, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) announced today the closing of its previously announced underwritten public offering of common stock. Precigen sold 17,250,000 shares of its common stock at a public offering price of $7.50 per share, including...
- 01/26/2021
|
Precigen Announces Pricing of $112.5 Million Public Offering of Common Stock
- GERMANTOWN, Md., Jan. 22, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $7.50 per share. Precigen has also granted the underwriters a 30-day option to...
- 01/22/2021
|
Precigen Announces Proposed Public Offering of Common Stock
- GERMANTOWN, Md., Jan. 21, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced an underwritten public offering of shares of its common stock. In addition, Precigen intends to grant the underwriters a 30-day option to purchase additional shares of its common...
- 01/21/2021
|
Precigen to Present at the 39th Annual J.P. Morgan Healthcare Conference
- GERMANTOWN, Md., Jan. 6, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will...
- 01/06/2021
|
Precigen Announces Clearance of IND to Initiate Phase I Study of PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)
- GERMANTOWN, Md., Jan. 5, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has cleared the...
- 01/05/2021
|
Precigen Provides Latest Clinical Developments at Virtual R&D Update Event
- GERMANTOWN, Md., Dec. 15, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today held an R&D virtual event to provide an update on the latest progress for...
- 12/15/2020
|
Precigen Presents New Data Supporting the Safety, Clinical Activity, Expansion and Persistence of PRGN-3006 UltraCAR-T® at the 62nd ASH Annual Meeting and Exposition
- GERMANTOWN, Md., Dec. 7, 2020 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced at the 62nd ASH Annual Meeting and Exposition (Abstract 2864) clinical progress...
- 12/07/2020
|
PGEN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Notifies Precigen, Inc. f/k/a Intrexon Corporation Shareholders of Class Action and Lead Plaintiff Deadline: December 4, 2020
- NEW YORK--(BUSINESS WIRE)--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Precigen, Inc. f/k/a Intrexon Corporation (“Precigen” or the "Company") (NASDAQ: PGEN) (NASDAQ: XON) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Precigen securities between May 10, 2017 and September 25, 2020, inclusive (the "Class Period"). Such investors are encouraged to join this case by
- 12/04/2020
|
PGEN DEADLINE TODAY: Hagens Berman, National Trial Attorneys, Alerts Precigen, Inc. (PGEN) Investors of Today's Deadline to Move for Lead Plaintiff
- San Francisco, California--(Newsfile Corp. - December 4, 2020) - Hagens Berman urges Precigen, Inc. (NASDAQ: PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have sufficient losses to move for lead plaintiff.Class Period: May 10, 2017 - Sept. 25, 2020Lead Plaintiff Deadline: Dec. 4, 2020Visit: www.hbsslaw.com/investor-fraud/PGENContact An Attorney Now: PGEN@hbsslaw.com844-916-0895Precigen, Inc. (PGEN) Securities Fr
- 12/04/2020
|
PGEN FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Reminds Precigen, Inc. f/k/a Intrexon Corporation Investors of Important December 4 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourage Investors with Losses in Excess of $100K to Contact Firm - PGEN, XON
- New York, New York--(Newsfile Corp. - December 3, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN) (NASDAQ: XON) between May 10, 2017 and September 25, 2020, inclusive (the "Class Period"), of the important December 4, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Precigen f/k/a Intrexon...
- 12/03/2020
|
DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Precigen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - December 3, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Precigen, Inc. ("Precigen" or "the Company") (NASDAQ: PGEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 10, 2017 and September 25, 2020, inclusive...
- 12/03/2020
|
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Precigen, Inc. f/k/a Intrexon Corporation of Class Action Lawsuit and Upcoming Deadline - PGEN
- NEW YORK, Dec. 3, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Precigen, Inc. f/k/a Intrexon Corporation ("Precigen" or the "Company") (NASDAQ: PGEN). The class action, filed in United States District Court for the...
- 12/03/2020
|
PGEN 2-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Alerts Precigen, Inc. (PGEN) Investors to Friday Application Deadline, Encourages Investors with Losses to Contact Its Attorneys
- San Francisco, California--(Newsfile Corp. - December 2, 2020) - Hagens Berman urges Precigen, Inc. (NASDAQ: PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have sufficient losses to move for lead plaintiff. Class Period: May 10, 2017 - Sept. 25, 2020Lead Plaintiff Deadline: Dec. 4, 2020Visit: www.hbsslaw.com/investor-fraud/PGEN Contact An Attorney Now: PGEN@hbsslaw.com ...
- 12/02/2020
|
PGEN Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Notifies Precigen, Inc. f/k/a Intrexon Corporation Shareholders of Class Action and Lead Plaintiff Deadline: December 4, 2020
- New York, New York--(Newsfile Corp. - December 2, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Precigen, Inc. f/k/a Intrexon Corporation ("Precigen" or the "Company") (NASDAQ: PGEN) (NASDAQ: XON) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Precigen securities between May 10, 2017 and September 25, 2020, inclusive (the "Class Period"). Such investors are encouraged to join this case...
- 12/02/2020
|
FRIDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Precigen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - December 2, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Precigen, Inc. (NASDAQ: PGEN) ("Precigen" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 10, 2017 and September 25, 2020, inclusive (the ''Class...
- 12/02/2020
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Precigen, Inc. (PGEN) Investors to December 4th Lead Plaintiff Deadline, Encourages Investors with Losses to Contact Its Attorneys
- SAN FRANCISCO, Dec. 1, 2020 /PRNewswire/ -- Hagens Berman urges Precigen, Inc. (NASDAQ: PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have sufficient losses to move for lead...
- 12/01/2020
|
FRIDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Precigen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - December 1, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Precigen, Inc. ("Precigen" or "the Company") (NASDAQ: PGEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 10, 2017 and September 25, 2020, inclusive...
- 12/01/2020
|
PGEN 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Precigen, Inc. (PGEN) Investors with Losses to Contact Its Attorneys, Securities Fraud Deadline Approaching
- San Francisco, California--(Newsfile Corp. - November 30, 2020) - Hagens Berman urges Precigen, Inc. (NASDAQ: PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have sufficient losses to move for lead plaintiff. Class Period: May 10, 2017 - Sept. 25, 2020Lead Plaintiff Deadline: Dec. 4, 2020Visit: www.hbsslaw.com/investor-fraud/PGEN Contact An Attorney Now: PGEN@hbsslaw.com ...
- 11/30/2020
|
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation (PGEN, XON)
- LOS ANGELES--(BUSINESS WIRE)---- $PGEN #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming December 4, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Precigen, Inc. (“Precigen” or the “Company”) f/k/a Intrexon Corporation (“Intrexon”) (NASDAQ: PGEN, XON) securities between May 10, 2017 and September 25, 2020, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On September 25
- 11/30/2020
|
FRIDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Precigen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - November 30, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Precigen, Inc. (NASDAQ: PGEN) ("Precigen" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 10, 2017 and September 25, 2020,...
- 11/30/2020
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Precigen, Inc. (PGEN) Investors to December 4th Investor Deadline, Encourages Investors with Losses to Contact Its Attorneys
- San Francisco, California--(Newsfile Corp. - November 29, 2020) - Hagens Berman urges Precigen, Inc. (NASDAQ: PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have sufficient losses to move for lead plaintiff. Class Period: May 10, 2017 - Sept. 25, 2020Lead Plaintiff Deadline: Dec. 4, 2020Visit: www.hbsslaw.com/investor-fraud/PGEN Contact An Attorney Now: PGEN@hbsslaw.com ...
- 11/29/2020
|
PGEN 6-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Precigen, Inc. (PGEN) Investors with Losses to Contact Its Attorneys, Securities Fraud Deadline Approaching
- SAN FRANCISCO, Nov. 28, 2020 (GLOBE NEWSWIRE) -- Hagens Berman urges Precigen, Inc. (N ASDAQ : PGEN ) (f/k/a Intrexon) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have sufficient losses to move for lead plaintiff.
- 11/28/2020
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Precigen, Inc. (PGEN) Investors of December 4th Application Deadline, Encourages Investors with Losses to Contact Its Attorneys
- San Francisco, California--(Newsfile Corp. - November 27, 2020) - Hagens Berman urges Precigen, Inc. (NASDAQ: PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have sufficient losses to move for lead plaintiff. Class Period: May 10, 2017 - Sept. 25, 2020Lead Plaintiff Deadline: Dec. 4, 2020Visit: www.hbsslaw.com/investor-fraud/PGEN Contact An Attorney Now: PGEN@hbsslaw.com ...
- 11/27/2020
|
7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Precigen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - November 27, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Precigen, Inc. (NASDAQ: PGEN) ("Precigen" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 10, 2017 and September 25, 2020, inclusive (the ''Class Period''),...
- 11/27/2020
|
PGEN INVESTOR DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Precigen Inc., f/k/a Intrexon Corporation
- NEW YORK, Nov. 27, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors that purchased or acquired the...
- 11/27/2020
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Precigen, Inc. (PGEN) Investors of December 4th Application Deadline, Encourages Investors with Losses to Contact Its Attorneys
- San Francisco, California--(Newsfile Corp. - November 25, 2020) - Hagens Berman urges Precigen, Inc. (NASDAQ: PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have sufficient losses to move for lead plaintiff. Class Period: May 10, 2017 - Sept. 25, 2020Lead Plaintiff Deadline: Dec. 4, 2020Visit: www.hbsslaw.com/investor-fraud/PGEN Contact An Attorney Now: PGEN@hbsslaw.com ...
- 11/25/2020
|
Scott+Scott Attorneys at Law LLP Alerts Investors to December 4 Lead Plaintiff Deadline in Securities Class Actions Against Precigen, Inc. (PGEN)
- NEW YORK--(BUSINESS WIRE)-- #Intrexon--Scott+Scott Attorneys at Law LLP Alerts Investors to December 4 Lead Plaintiff Deadline in Securities Class Actions Against Precigen, Inc. (PGEN)
- 11/25/2020
|
ROSEN, A TOP RANKED LAW FIRM, Reminds Precigen, Inc. f/k/a Intrexon Corporation Investors of Important December 4 Deadline in First Filed Securities Class Action Commenced by the Firm - PGEN, XON
- New York, New York--(Newsfile Corp. - November 23, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN) (NASDAQ: XON) between May 10, 2017 and September 25, 2020, inclusive (the "Class Period"), of the important December 4, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Precigen f/k/a Intrexon...
- 11/23/2020
|
PGEN SHAREHOLDER UPDATE: Hagens Berman, National Trial Attorneys, Encourages Precigen, Inc. (PGEN), f/k/a Intrexon Corp. (XON) Investors with Losses to Contact Its Attorneys, Securities Fraud Deadline Approaching
- San Francisco, California--(Newsfile Corp. - November 17, 2020) - Hagens Berman urges Precigen, Inc. (NASDAQ: PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims.Class Period: May 10, 2017 - Sept. 25, 2020Lead Plaintiff Deadline: Dec. 4, 2020Visit: www.hbsslaw.com/investor-fraud/PGENContact An Attorney Now: PGEN@hbsslaw.com844-916-0895Precigen, Inc. (PGEN) Securities Fraud Class Action: The complaint alleges tha
- 11/17/2020
|
Precigen Announces Dosing of First Patients with UltraCAR-T® Cells Manufactured Using Proprietary UltraPorator™ System in Ongoing PRGN-3005 and PRGN-3006 Phase 1 Clinical Trials
- GERMANTOWN, Md., Nov. 16, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical implementation of its UltraPorator™ system, a device...
- 11/16/2020
|
ROSEN, A LEADING LAW FIRM, Reminds Precigen, Inc. f/k/a Intrexon Corporation Investors of Important December 4 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $100K to Contact Firm - PGEN, XON
- New York, New York--(Newsfile Corp. - November 13, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN) (NASDAQ: XON) between May 10, 2017 and September 25, 2020, inclusive (the "Class Period"), of the important December 4, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Precigen f/k/a Intrexon investors...
- 11/13/2020
|
Precigen: Q3 Earnings Insights
- Shares of Precigen (NASDAQ:PGEN) were unchanged after the company reported Q3 results.
- 11/09/2020
|
Precigen Reports Third Quarter 2020 and Year-to-Date Financial Results
- GERMANTOWN, Md., Nov. 9, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter and year-to-date financial results for 2020....
- 11/09/2020
|
ROSEN, A LEADING LAW FIRM, Reminds Precigen, Inc. f/k/a Intrexon Corporation Investors of Important December 4 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $100K to Contact Firm - PGEN, XON
- New York, New York--(Newsfile Corp. - November 4, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN) (NASDAQ: XON) between May 10, 2017 and September 25, 2020, inclusive (the "Class Period"), of the important December 4, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Precigen f/k/a Intrexon investors...
- 11/04/2020
|
PGEN SECURITIES FRAUD: Hagens Berman, National Trial Attorneys, Encourages Precigen, Inc. (PGEN), f/k/a Intrexon Corp. (XON) Investors with Losses to Contact Its Attorneys, Securities Fraud Action Filed, Investor Deadlines Established
- San Francisco, California--(Newsfile Corp. - November 3, 2020) - Hagens Berman urges Precigen, Inc. (NASDAQ: PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims. Class Period: May 10, 2017 - Sept. 25, 2020Lead Plaintiff Deadline: Dec. 4, 2020Visit: www.hbsslaw.com/investor-fraud/PGEN Contact An Attorney Now: PGEN@hbsslaw.com 844-916-0895Precigen, Inc. (PGEN) Securities...
- 11/03/2020
|
Miller Value Partners is Betting on Precigen (PGEN) Stock
- Miller Value Partners recently released its Q3 2020 Investor Letter, a copy of which you can download here. The Opportunity Equity Fund posted a return of 13.01% for the quarter (net of fees), outperforming its benchmark, the S&P 500 Index which returned 8.93% in the same quarter. You should check out Miller Value Partners' top 5 stock picks for investors to buy right now, which could be the biggest winners of this year.
- 11/02/2020
|
PGEN SHAREHOLDER ALERT: Hagens Berman, National Trial Attorneys, Encourages Precigen, Inc. (PGEN), f/k/a Intrexon Corp. (XON), Investors with Losses to Contact Its Attorneys, Securities Fraud Action Filed, Application Deadline Approaching
- San Francisco, California--(Newsfile Corp. - October 29, 2020) - Hagens Berman urges Precigen, Inc. (NASDAQ: PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims.Class Period: May 10, 2017 - Sept. 25, 2020Lead Plaintiff Deadline: Dec. 4, 2020Visit: www.hbsslaw.com/investor-fraud/PGENContact An Attorney Now: PGEN@hbsslaw.com844-916-0895Precigen, Inc. (PGEN) Securities Fraud Class Action: The complain
- 10/29/2020
|
ROSEN, A LEADING LAW FIRM, Reminds Precigen, Inc. f/k/a Intrexon Corporation Investors of Important December 4 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $100K to Contact Firm - PGE
- NEW YORK, Oct. 29, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN, XON) between May 10, 2017 and September 25, 2020, inclusive (the "Class Period"), of the important...
- 10/29/2020
|
PGEN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation
- LOS ANGELES--(BUSINESS WIRE)---- $PGEN #CLASSACTION--PGEN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation
- 10/28/2020
|
ROSEN, RESPECTED INVESTOR COUNSEL, Reminds Precigen, Inc. f/k/a Intrexon Corporation Investors of Important December 4 Deadline in First Filed Securities Class Action Commenced by the Firm - PGEN, XON
- New York, New York--(Newsfile Corp. - October 28, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN) (NASDAQ: XON) between May 10, 2017 and September 25, 2020, inclusive (the "Class Period"), of the important December 4, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Precigen f/k/a Intrexon investors...
- 10/28/2020
|
Pomerantz Law Firm Announces the Filing of a Class Action against Precigen, Inc. f/k/a Intrexon Corporation Certain Officers - PGEN
- NEW YORK, Oct. 26, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Precigen, Inc. f/k/a Intrexon Corporation ("Precigen" or the "Company") (NASDAQ: PGEN). The class action, filed in United States District Court for the...
- 10/26/2020
|
DEADLINE REMINDER: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation (PGEN, XON)
- BENSALEM, Pa., Oct. 26, 2020 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming December 4, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Precigen, Inc. ("Precigen" or the "Company") f/k/a...
- 10/26/2020
|
